BioCardia Achieves Nasdaq Compliance
BioCardia, Inc. (NASDAQ: BCDA), known for its innovative cellular and cell-derived therapies for cardiovascular and pulmonary diseases, has some promising news. The company has announced that it has regained full compliance with the Nasdaq Capital Market's listing requirements following a thorough review by the Hearing Panel.
Compliance Announcement Details
Recently, BioCardia received an official notice from Nasdaq confirming that it has complied with Listing Rule 5550(b)(1), commonly referred to as the Equity Rule. This important development ensures that the Company’s securities can continue to be listed on the Nasdaq Stock Market without any interruptions.
Recent Progress and Developments
The announcement of compliance comes on the heels of BioCardia’s concerted efforts to improve its financial standing. The company has successfully raised new capital to support ongoing projects for its therapeutic candidates and to enhance its already approved products. These efforts reflect a strong commitment to innovation and patient care in the healthcare industry.
FDA Approvals and Clinical Trials
Recently, BioCardia made significant strides, notably the approval of the CardiAMP Cell Therapy Heart Failure II protocol amendment. This approval allows incorporation of their proprietary Cell Population Analysis screening method, which customizes treatment plans for each patient. Additionally, the University of Wisconsin has now treated the final participant in the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial.
Collaborations and Future Directions
BioCardia’s progress is further supported by its collaborations, such as with Helix™ partner CellProthera, which received positive feedback from the FDA during a pre-IND meeting regarding their cell therapy targeting acute myocardial infarction. Moreover, the company has achieved FDA market clearance for its Morph® DNA™ product line, representing a significant milestone in its product portfolio.
BioCardia’s Vision
Peter Altman, PhD, President and CEO of BioCardia, expressed his enthusiasm about the company's advancements. He stressed their commitment to developing innovative therapies for cardiovascular and pulmonary diseases. Looking ahead, BioCardia is focused on finalizing the CardiAMP HF I trial data for regulatory review while initiating patient randomization in the pivotal confirmatory CardiAMP HF II trial.
About BioCardia
Based in Sunnyvale, California, BioCardia leads the way in cellular and cell-derived therapeutic solutions. Their CardiAMP® autologous and CardiALLO™ allogeneic cell therapies represent cutting-edge biotherapeutic platforms currently under clinical development. These pioneering therapies not only underscore BioCardia's drive to advance medical science but also highlight its dedication to patient-centered care.
Frequently Asked Questions
What does it mean for BioCardia to regain compliance with Nasdaq?
Regaining compliance indicates that BioCardia has met Nasdaq’s listing standards, enabling it to continue trading its shares without any interruptions.
What recent regulatory approvals has BioCardia obtained?
BioCardia has recently secured approval for the CardiAMP Cell Therapy Heart Failure II protocol amendment and market clearance for the Morph® DNA™ product line.
What are the primary products offered by BioCardia?
BioCardia's key offerings include the CardiAMP® and CardiALLO™ cell therapies for cardiovascular and pulmonary issues, along with the Morph® vascular navigation product platforms.
How does BioCardia plan to utilize its recent capital raise?
The capital raised will support BioCardia in advancing the development of its current therapeutic candidates and enhancing its approved products in the market.
Who should I contact for more information about BioCardia?
If you have media inquiries, please contact Miranda Peto at 650-226-0120 or via email at mpeto@BioCardia.com. For investor-related questions, reach out to David McClung at the same phone number or email investors@BioCardia.com.
